What do the most current guidelines recommend for use of non-statin therapies in management of atherosclerotic cardiovascular disease (ASCVD)? Find out what you already know and what you may need to brush up on with this short quiz based on the 2017 update to the ACC Expert Consensus Decision Pathway (ECDP) on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.1
1. According to the 2013 ACC/AHA Guideline for Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults,2 which of the following is NOT a statin benefit group?
A. Adults aged ≥ 21 years with clinical ASCVD.
B. Adults aged ≥ 21 years with LDL-C ≥ 170 mg/dL.
C. Adults aged 40-75 years without ASCVD but with diabetes and with LDL-C between 70-189 mg/dL.
D. Adults aged 40-75 years without ASCVD or diabetes and with LDL-C 79-189 mg/dL and estimated 10-year risk for ASCVD ≥ 7.5%.
Please click for answer, discussion, and next question.